ArticleThe Journal of experimental medicine1996
Recognition of class I major histocompatibility complex molecules by Ly-49: specificities and domain interactions.
Article in The Journal of experimental medicine, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 101 citations in OpenAlex.
- Ly49G, but not Ly49C/I, is dispensable for diverse antigen-specific memory NK cell responses in H-2d and H-2b mice.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- The activating Ly49W and inhibitory Ly49G NK cell receptors display similar affinities for identical MHC class I ligands.Immunogenetics · 2014Article
- Natural killer cell licensing in mice with inducible expression of MHC class I.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Targeting of a natural killer cell receptor family by a viral immunoevasin.Nature immunology · 2013Article
- Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells.Nature immunology · 2012Article
- The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation.Immunity · 2012Article
- Cytomegalovirus immunoevasin reveals the physiological role of "missing self" recognition in natural killer cell dependent virus control in vivo.The Journal of experimental medicine · 2010Article
- Distinct conformations of Ly49 natural killer cell receptors mediate MHC class I recognition in trans and cis.Immunity · 2009Article
- Probing natural killer cell education by Ly49 receptor expression analysis and computational modelling in single MHC class I mice.PloS one · 2009Article
- Gammadelta T lymphocyte homeostasis is negatively regulated by beta2-microglobulin.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- NK gene complex dynamics and selection for NK cell receptors.Seminars in immunology · 2008Review
- Molecular architecture of the major histocompatibility complex class I-binding site of Ly49 natural killer cell receptors.The Journal of biological chemistry · 2008Article
- Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model.Cancer immunology, immunotherapy : CII · 2008Article
- Stable masking by H-2Dd cis ligand limits Ly49A relocalization to the site of NK cell/target cell contact.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- An innately interesting decade of research in immunology.Nature medicine · 2004Review
- Genomic organization and evolutionary analysis of Ly49 genes encoding the rodent natural killer cell receptors: rapid evolution by repeated gene duplication.Immunogenetics · 2004Article
- Receptor/ligand avidity determines the capacity of Ly49 inhibitory receptors to interfere with T-cell receptor-mediated activation.Immunology · 2003Article
- Immune functions encoded by the natural killer gene complex.Nature reviews. Immunology · 2003Review
- H-2D ligand expression by Ly49A+ natural killer (NK) cells precludes ligand uptake from environmental cells: implications for NK cell function.The Journal of experimental medicine · 2001Article
- Expression of natural killer receptor alleles at different Ly49 loci occurs independently and is regulated by major histocompatibility complex class I molecules.The Journal of experimental medicine · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ly-49 is a family type II transmembrane proteins encoded by a gene cluster on murine chromosome 6. One member of this family, Ly-49A, is expressed by a natural killer (NK) cell subset, binds to class I major histocompatibility complex (MHC) molecules, and blocks the killing of target cells bearing the appropriate H-2 antigens. Here we show that another member of this family which is expressed by an NK cell subset, Ly-49C, recognizes H-2b and H-2d structures which are distinct from and overlapping with those recognized by Ly-49A. Interactions between Ly-49A and C and their class I ligands are entirely blocked by the antibodies 5E6, YE1/48, YE1/32, and A1, all of which were found to recognize epitopes contained within the carbohydrate recognition domain (CRD). However, cell-cell binding assays revealed that class I binding specificity is conferred by a combination of sequences within both the CRD and a 19-amino acid adjacent region. We also investigated the question of whether Ly-49A and C form dimers on cells which express both receptors. When coexpressed on COS cells, sequential immunoprecipitation demonstrated that these receptors pair exclusively as homodimers, with no evidence for heterodimeric structures. These observations provide insight into both the biochemical nature of the Ly-49 family as well as the receptor functions of Ly-49C on NK cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.